KARPAS 384

6120602, human blood, Large clumps growing slowly in suspension

• Synonym(e): KARPAS, 384, KARPAS-384, KARPAS384
• UNSPSC-Code: 41106514

Eigenschaften

• product name: KARPAS 384, from human blood, 06120602
• Biologische Quelle: human blood
• Wachstumsmodus: Suspension
• Karyotyp: Complex, refer to Dyer et al., 1993
• Morphologie: Large clumps growing slowly in suspension
• Produkte: Not specified
• Rezeptoren: Not specified
• Methode(n): cell culture | mammalian: suitable
• Relevante Krankheit(en): cancer
• Versandbedingung: dry ice

Beschreibung

Ursprung der Zelllinie

Human T-cell non-Hodgkin lymphoma

Beschreibung der Zelllinie

Established from peripheral blood of a 48 year-old male with widespread subcutaneous nodules. Biopsy showed high grade Non-Hodgkin lymphoma with numerous mitoses.

DNA-Profil

Not specified

Nährmedium

RPMI 1640 + 2 mM Glutamine + 10% Fetal Bovine Serum (FBS)

Subkultur-Routine

Doubling time approximately 60 hours. Cells grow slowly in suspension in large clumps. Maintain cultures between 3-9 x 10⁵ cells/ml; 5% CO₂; 37 °C. Thaw ampoule and perform a cell count, spin out the DMSO and resuspend in an appropriate volume of media to give a cell concentration of 4-5 x 10⁵ cells/ml. Viability may be poor on resuscitation and may decrease further within the first 48 hours, the culture may appear non-viable at this time. Clusters of cells will eventually appear but this could take 1-2 weeks, during this time large media changes are not recommended. It may take 2-3 weeks for vigorous growth to be established. At subculture perform a cell count and maintain cultures between 3-9 x 10⁵ cells/ml, 5% CO₂, 37 °C. For cryopreservation of KARPAS 384, freeze at approximately 2 x 10⁷ cells/ml in 90% FBS + 10% DMSO.

Sonstige Hinweise

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Haftungsausschluss

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.